Suppr超能文献

针对人端粒酶逆转录酶(hTERT)的小干扰RNA(siRNA)对端粒酶的抑制作用会导致HT29细胞中的端粒损耗。

Telomerase inhibition by an siRNA directed against hTERT leads to telomere attrition in HT29 cells.

作者信息

de Souza Nascimento Patrícia, Alves Gilda, Fiedler Wolfgang

机构信息

Klinik und Poliklinik f. Innere Medizin I - Sektion Molekulare Gastroenterologische Onkologie, Martin Luther Universität Halle-Wittenberg, Halle, Germany.

出版信息

Oncol Rep. 2006 Aug;16(2):423-8.

Abstract

Human telomerase is a ribonucleoprotein complex composed of at least the reverse catalytic transcriptase hTERT and RNA component hTR. The enzyme stabilizes telomere length and thereby contributes to unlimited cell proliferation, i.e. immortality. Reactivation of telomerase activity during carcinogenesis is a common hallmark in most human tumor types. Consequently, telomerase is an attractive molecular target toward which to direct cancer therapeutic agents. RNA interference (RNAi) has been shown to be an effective method for inhibiting the expression of a given gene in human cells by targeting with short duplex RNA (short-interfering RNA or siRNA). Thus, we evaluated the ability of siRNAs to inhibit telomerase activity in the HT29 immortal human colorectal adenocarcinoma cell line as a model for colorectal carcinogenesis. By transient expression of a specific siRNA directed against hTERT, we reduced telomerase activity in the transfected cells. Moreover, telomere lengths were reduced in cells stably expressing this particular RNA sequence, cloned as an shRNA into an eukaryotic expression vector. The cell clone that displayed a telomerase-negative phenotype showed dramatically reduced telomere lengths and stopped proliferation. We observed that the vector was integrated into the cell genome and, despite telomere shortening, cells retained their MSI phenotype. We conclude that we have developed a potent telomerase inhibitor leading to cell death.

摘要

人端粒酶是一种核糖核蛋白复合体,至少由逆转录催化酶hTERT和RNA组分hTR组成。该酶可稳定端粒长度,从而促进细胞无限增殖,即永生。在癌变过程中端粒酶活性的重新激活是大多数人类肿瘤类型的一个常见特征。因此,端粒酶是一个有吸引力的分子靶点,可用于指导癌症治疗药物的研发。RNA干扰(RNAi)已被证明是一种通过用短双链RNA(小干扰RNA或siRNA)靶向抑制人类细胞中特定基因表达的有效方法。因此,我们评估了siRNA抑制HT29永生人结肠直肠腺癌细胞系中端粒酶活性的能力,以此作为结肠直肠癌发生的模型。通过瞬时表达针对hTERT的特异性siRNA,我们降低了转染细胞中的端粒酶活性。此外,稳定表达克隆到真核表达载体中作为shRNA的这个特定RNA序列的细胞,其端粒长度缩短。表现出端粒酶阴性表型的细胞克隆显示端粒长度显著缩短并停止增殖。我们观察到该载体整合到细胞基因组中,尽管端粒缩短,但细胞仍保留其微卫星不稳定性(MSI)表型。我们得出结论,我们已经开发出一种有效的端粒酶抑制剂,可导致细胞死亡。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验